Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

NCT05660980 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

NCT04399551 ·Status: COMPLETED ·Phase: PHASE3

Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine

NCT06403865 ·Status: NOT_YET_RECRUITING

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05917509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805 ·Status: RECRUITING ·Phase: PHASE3

Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy

NCT05697289 ·Status: UNKNOWN

CAbotégravir LENacapavir DUal Long Acting

NCT06657885 ·Status: WITHDRAWN ·Phase: PHASE2

Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

NCT06507059 ·Status: RECRUITING ·Phase: PHASE3

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

NCT05896748 ·Status: COMPLETED ·Phase: PHASE3

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

NCT04001803 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N

NCT05349838 ·Status: COMPLETED ·Phase: PHASE3

REal-Life Cohort With DOlutegravir + LAmivudina

NCT04638686 ·Status: COMPLETED

Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset

NCT06834113 ·Status: RECRUITING ·Phase: NA

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

NCT01049685 ·Status: UNKNOWN ·Phase: PHASE4

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935 ·Status: COMPLETED ·Phase: PHASE3

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

NCT03539224 ·Status: UNKNOWN ·Phase: PHASE2

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

NCT06138600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

NCT06273943 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

NCT00532168 ·Status: COMPLETED ·Phase: PHASE4

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

NCT03683524 ·Status: COMPLETED ·Phase: PHASE4

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243 ·Status: COMPLETED ·Phase: PHASE3

Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

NCT03732625 ·Status: UNKNOWN ·Phase: PHASE4

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011 ·Status: COMPLETED ·Phase: PHASE3